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Advances in Antisense Oligonucleotide Development for 
Target Identifi cation, Validation, and as Novel Therapeutics
Moizza Mansoor and Alirio J. Melendez
Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Abstract: Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands of deoxynucleotide 
sequences, usually 18–21 nucleotides in length, complementary to the mRNA sequence of the target gene. As-ODNs are 
able to selectively bind cognate mRNA sequences by sequence-specifi c hybridization. This results in cleavage or disable-
ment of the mRNA and, thus, inhibits the expression of the target gene. The specifi city of the As approach is based on the 
probability that, in the human genome, any sequence longer than a minimal number of nucleotides (nt), 13 for RNA and 17 
for DNA, normally occurs only once. The potential applications of As-ODNs are numerous because mRNA is ubiquitous 
and is more accessible to manipulation than DNA. With the publication of the human genome sequence, it has become 
theoretically possible to inhibit mRNA of almost any gene by As-ODNs, in order to get a better understanding of gene 
function, investigate its role in disease pathology and to study novel therapeutic targets for the diseases caused by dysregu-
lated gene expression. The conceptual simplicity, the availability of gene sequence information from the human genome, 
the inexpensive availability of synthetic oligonucleotides and the possibility of rational drug design makes As-ODNs pow-
erful tools for target identifi cation, validation and therapeutic intervention. In this review we discuss the latest developments 
in antisense oligonucleotide design, delivery, pharmacokinetics and potential side effects, as well as its uses in target iden-
tifi cation and validation, and fi nally focus on the current developments of antisense oligonucleotides in therapeutic interven-
tion in various diseases.
Introduction
Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands of deoxy-
nucleotide sequences, usually 18–21 nucleotides in length, complementary to the mRNA sequence of 
the target gene. As-ODNs are able to selectively bind cognate mRNA sequences by sequence-specifi c 
hybridization. This results in cleavage or disablement of the mRNA and, thus, inhibits the expression 
of the target gene. The specifi city of the As approach is based on the probability that, in the human 
genome, any sequence longer than a minimal number of nucleotides (nt), 13 for RNA and 17 for DNA, 
normally occurs only once [1].
The modifi cation of gene expression, using a synthetic single stranded DNA, resulting in inhibition 
of mRNA translation was demonstrated for the fi rst time by Paterson et al. in 1977 in a cell-free 
system [2]. Almost a year later, Zamecnik and Stephenson showed that in chicken fi broblast tissue 
culture containing Rous Sarcoma virus, addition of a synthetic13 mer ODN complementary to the 
3’ terminal sequence of the Rous sarcoma virus, could inhibit viral replication and transformation of 
fi broblasts into sarcoma cells [3].
These seminal papers, and the thousands that followed, have caused enormous progress towards the 
development of a new class of drugs, As-ODNs.
The potential applications of As-ODNs are numerous because mRNA is ubiquitous and is more 
accessible to manipulation than DNA. With the publication of the human genome sequence, it has 
become theoretically possible to inhibit mRNA of almost any gene by As-ODNs, in order to get a bet-
ter understanding of gene function, investigate its role in disease pathology and to study novel thera-
peutic targets for the diseases caused by dysregulated gene expression. The conceptual simplicity, the 
availability of gene sequence information from the human genome, the inexpensive availability of 
synthetic oligonucleotides and the possibility of rational drug design makes As-ODNs powerful tools 
for target identifi cation and therapeutic intervention [4]. However, initial studies of As-ODNs, which 
276
Mansoor and Melendez
Gene Regulation and Systems Biology 2008:2 
utilized deoxyribonucleotides, were disappointing, 
as they were limited by a number of factors such 
as the poor solubility of ODNs, weak permeation 
across biological membranes and rapid degradation 
by endo and exo nucleases [5]. For As-ODNs to 
be therapeutically effective, it was necessary to 
improve their stability and effi cacy while retaining 
their specifi city. For this purpose several chemical 
modifi cations have been made to various compo-
nents of As-ODNs, resulting in improvements in 
their stability, potency and bioavailability. On the 
basis of these modifi cations, As-ODNs can now 
be broadly classifi ed into 3 generations: As-ODNs 
with altered phosphate backbone, those with 
modifi ed sugars and those containing unnatural 
bases [6] (Fig. 1).
Advances in the Design of
Antisense Oligonucleotides
First-generation antisense 
oligonucleotides
The fi rst generation ODNs are synthesized by 
replacing one of the non-bridging oxygen atoms 
in the phosphate group with either a sulfur group 
(phosphorothioates), methyl group (methyl phos-
phonates) or amines (phosphoramidates). The fi rst 
generation ODNs have more resistance to nucle-
ases and longer plasma half life as compared with 
phosphodiester oligonucleotides. Moreover, they 
are easy to synthesize, carry negative charges that 
ease their cell delivery, are capable of activating 
RNAse H and have suitable pharmacokinetics [7]. 
At present, the phosphorothioate is the most widely 
used As-ODN modifi cation and phosphorothioate 
oligonucleotides (PS-ODNs) have shown promis-
ing results both in vivo and in vitro. The only FDA 
approved As-ODN drug, Vitravene, and most of 
the other drugs in clinical trials are PS-ODNs.
However, as discussed to be later, fi rst generation 
As-ODNs produce various undesirable, non-
specific in vivo side effects, such as immune 
stimulation and complement activation, which are 
mainly caused by their interactions with proteins.
Second-generation antisense 
oligonucleotides
To improve the binding affi nity and hybridization 
stability with target mRNA and to increase the 
nuclease resistance, second generation As-ODNs, 
with alkyl modifi cations at the 2’ position of the 
ribose, were developed. The most commonly used 
second generation As-ODNs are 2’-O- Methyl (2’-
OME) and 2’-O-Methoxyethyl (2’-MOE) ODNs. 
However, the useful effects of these modifi cations 
are dampened by the fact that they render 2’-OME 
and 2’-MOE incapable of activating RNAse H, an 
endonuclease whose recruitment is considered to 
be important for the activity of As-ODNs [8]. To 
induce RNAse H activation, chimeric As-ODNs 
were developed, by surrounding a central gap 
region consisting of a phosphorothioate deoxyri-
bose core, with nuclease resistant arms such as 
2’-OME or 2’-MOE. The resulting “gapmer” 
allows RNAse H to sit in the central gap to activate 
target specifi c mRNA degradation, while the arms, 
by virtue of alkyl modifi cations, prevent the deg-
radation of As-ODNs by nucleases [9].
Second generation As-ODNS are reported to 
have a higher affi nity for mRNA, better tissue 
uptake, increased resistance to nucleases, longer 
in vivo half life and lesser toxicity, as compared to 
fi rst generation As-ODNs [10]. GEM 231 and 
GEM 92 (Hybridon) are examples of second gen-
eration As-ODNs currently being tested in the 
clinical trials.
Third-generation antisense 
oligonucleotides
Third generation As-ODNs were developed by 
chemically modifying the furanose ring of the 
ODNs, along with modifi cations of phosphate 
linkages or of riboses, as well as of nucleotides. 
The modifications were made to improve the 
nuclease stability, target affi nity and pharmacoki-
netic profi les of the ODNs. Locked nucleic acid 
(LNA), Peptide nucleic acid (PNA) and Morpho-
lino phosphoroamidates (MF) are the three most 
commonly used third generation As-ODNs.
Third generation As-ODNs have higher stabil-
ity in biological fl uids as they are essentially 
resistant to degradation by nucleases and pepti-
dases. They also exhibit a strong hybridization 
affi nity with the mRNA. In addition, PNAs, due 
to their ability to recognize double stranded DNA, 
are capable of modulating gene expression or 
inducing mutation by strand invasion of chromo-
somal duplex DNA. However, third generation 
As-ODNs do not activate RNAse H and most 
likely produce their biological effects by causing 
steric hindrance of ribosomal machinery, resulting 
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Figure 1. Structure of fi rst, second and third generation antisense oligonucleotides.
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in translational arrest. Moreover, being uncharged 
molecules, they do not bind to serum proteins that 
normally bind poly anions. On the one hand, this 
reduces the likelihood of non-specifi c interac-
tions, but on the other hand, hastens their clear-
ance from the body. Also, their electrostatically 
neutral backbones make their solubility and 
uptake diffi cult [6]. To overcome these problems, 
in vitro, their delivery can be improved by 
employing the delivery systems mentioned later 
in this chapter.
Substantial data has demonstrated the effective-
ness of third generation As-ODNs in various in 
vitro, ex vivo and in vivo models. PNAs, MFs and 
LNAs As-ODNs have shown promising results in 
various studies [11–13]. In addition, the effi cacy 
of LNAs can be further increased by their ability 
to get freely incorporated in DNA to form chime-
ric gapmers, whereby a central DNA portion is 
fl anked on both sides by LNAs. Such chimeric 
LNA-ODNs allow the improved affi nity and higher 
nuclease resistance of LNA to be combined with 
the ability of gapmers to recruit RNAse H [14].
Mechanism of Action of Antisense 
Oligonucleotides
As-ODNs are designed to modulate the expression 
of proteins encoded by the mRNA, by binding and 
interfering with the function of target mRNA. Prior 
to protein synthesis, mRNA undergoes a range of 
essential processing steps such as 5’-capping, 
polyadenylation, intron—exon splicing, nuclear 
export, cytoplasmic stabilization and ribosomal 
binding. All of these steps are crucial for the syn-
thesis and function of mRNA and are highly regu-
lated. By interfering with any one of these 
processing reactions, As-ODNs can produce their 
inhibitory effects (Fig. 2).
A most important mechanism employed by As-
ODNs to cause the knockdown of proteins is the 
activation of RNAse H enzyme. RNAse H is a 
Figure 2. Mechanism of action of antisense oligonucleotides. As-ODN enters the cell and interacts with the target mRNA by sequence-specifi c 
base pairing. The As-ODN-mRNA duplex then prevents protein synthesis by interfering with various steps of mRNA synthesis.
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ubiquitously expressed endonuclease that recognizes 
and hydrolyzes the RNA strand of the mRNA-
olignucleotide heteroduplex [15]. The cleavage 
leaves As-ODNs intact and free to bind to another 
copy of mRNA. This recycling of As-ODNs makes 
their effect long lasting, making it possible to use 
them in micro or nano molar concentrations. As-
ODN mediated RNAse H-dependent downregula-
tion of mRNA is quite effi cient and can be up to 
85%–95% of the control levels. The chemistry of 
the mRNA-oligonucleotide duplex decides whether 
or not it will be recognized by RNAse H. While 
phosphodiester and PS-ODNs can be recognized 
by RNAse H, the majority of other sugar or back-
bone modifi cations render the As-ODN incapable 
of activating RNAse H. It is also important to note 
that RNAse H activity is located predominantly in 
the nucleus and thus the nuclear localization 
of RNAse-dependent As-ODNs becomes virtually 
essential for their function [16].
As-ODNs, which are not able to activate 
RNAse H, produce their effects by targeting other 
steps of the mRNA synthesis. These other mecha-
nisms of As-ODN inhibition can be classifi ed into 
either “occupancy only mediated mechanisms” or 
“occupancy activated destabilization” [17].
“Occupancy only mediated mechanisms” 
exploit the binding of As-ODNs to their specifi c 
sequences in mRNA, thus inhibiting the interaction 
of mRNA with nucleic acids, proteins and other 
factors vital for its processing. One such step is the 
splicing of mRNA that involves the excision of 
non-protein coding intervening RNA sequences 
(introns). The splicing reactions are sequence-
specifi c and require the concerted action of spli-
ceosomes. Therefore, the As-ODNs that bind to 
the sequences required for splicing will either 
physically prevent the required cleavage reactions 
or will prevent the binding of necessary factors. 
This will eventually result in inhibition of the 
production of the mature protein [17]. The modu-
lation of splicing by As-ODNs can also be used for 
the correction of aberrant splicing and restoration 
of a functional protein [18].
Another mechanism by which As-ODNs can 
downregulate expression of mRNA is by inhibi-
tion of mRNA translation. As-ODNs directed to 
the translation initiation codon of mRNA can 
bind to it, resulting in the blockade of protein 
translation [19].
“Occupancy activated destabilization” methods 
target the steps of mRNA synthesis that are 
essential for its stabilization, such as 5’ capping or 
3’ polyadenylation of mRNA. 5’ capping is crucial 
not only for the stability of mRNA, but also plays 
a role in its binding to the nuclear matrix and its 
transport out of the nucleus. Likewise, polyadenyl-
ation is essential for the stability and transport of 
mRNA. Therefore, As-ODNs designed against the 
5’ or 3’ region of pre-mRNA can prevent its 
capping or Polyadenylation, resulting in the desta-
bilization and disintegration of mRNA [17].
Delivery of Antisense 
Oligonucleotides: In Vitro 
and in Vivo
As-ODNs enter the cells mainly by endocytosis 
[20], caveolar potocytosis [21] or by pinocytosis 
[22] and accumulate in the endosomal/lysosomal 
compartment. Most of the As-ODN is degraded 
there and only the small portion that escapes to the 
cytoplasm and the nucleus is responsible for its 
pharmacological effects [20, 21].
In order to produce their biological effects, it is 
crucial for As-ODNs to be able to effectively 
penetrate the target cells. However, various bio-
logical barriers hinder the transport of As-ODNs to 
the target site. The large size and ionic charges of 
As-ODNs makes it relatively diffi cult to cross the 
plasma membrane. Moreover, As-ODNs need to 
cross the endosomal/lysosomal barrier and escape 
degradation by nucleases, in order to reach the 
target site, otherwise their concentration at the 
target site may become too low to produce any 
signifi cant biological effect [23]. Lastly, for effec-
tive systemic therapy, the integrity of As-ODNs 
must be maintained in the blood for a suffi cient 
length of time to allow As-ODNs to reach their 
target sites [24]. Therefore, as discussed earlier, 
modifi cations have been made in As-ODN structure 
to improve their bioavailability. In addition, a large 
variety of delivery systems have been developed to 
enhance the cellular uptake of As-ODNs, to protect 
them from degradation and to improve their intra-
cellular, and especially, intranuclear delivery.
ODN-lipid conjugates or liposome formulations 
are most commonly used as As-ODNs carriers in 
vitro. Cationic liposomes, such as Lipofectin and 
Transfectam, encapsulate As-ODNs to protect 
them from nuclease degradation and neutralize 
their negative charge to ease their entry into the 
cell: the addition of fusogenic lipids, such as 
dioleyl phosphatidylethanolamine (DOPE), to 
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liposome formulations aids in destabilizing the 
endosomal membrane, thus facilitating the delivery 
of As-ODNs to the target site [25–27]. However, 
cationic liposomes exhibit a markedly decreased 
activity in the presence of serum and antibiotics. 
Moreover, their utility is limited in vivo because 
of their toxicity and serum sensitivity [28].
Carrier molecules, that utilize receptor medi-
ated endocytosis (RME), make use of import 
mechanisms already present in the cell membrane 
for the transport of essential nutrients. As-ODNs 
are linked to the carrier proteins, either by covalent 
bond, or can be linked non-covalently via poly-l-
lysine -carrier conjugates. The choice of the carrier 
depends on its ability to bind to a certain cell 
surface receptor, allowing As-ODNs to be deliv-
ered effectively to target cells that express or 
over-express that particular receptor [29, 30]. 
Covalent conjugation of As-ODNs to macromol-
ecules, like dendimers, has also been shown to 
enhance the uptake and retention of As-ODNs in 
the cells. Unlike liposome formulations, the com-
plexes of As-ODNs and dendimers are stable in 
the presence of serum [31, 32]. Peptides, such as 
fusogenic peptides that aid in the fusion of ODN—
peptide conjugates with the cellular membranes, 
signal import peptides that improve the cellular 
uptake of As-ODNs or nuclear localization signal 
(NLS) peptides that help in targeting the ODNs to 
the nucleus, have also shown to be effective in 
in-vitro studies [33–35]. Covalent coupling of 
As-ODNs to these peptides allows them to enter 
the cells by receptor and transporter independent 
mechanisms, thus enhancing their penetration into 
the cells. Biodegradable nanoparticles have also 
been investigated as delivery vehicles for As-
ODNs. ODNs are adsorbed to the surface of 
nanoparticles by hydrophobic interactions. To 
promote the binding between As-ODNs and 
nanoparticles, hydrophobic cations, such as quar-
ternary ammonium salts, are usually used. 
Although in vitro studies have shown nanoparti-
cles to be effective carriers of As-ODNs [36], 
little is known about their in vivo effi cacy.
Another approach to enhance As-ODN inter-
nalization into the cells is to generate transient 
permeabilization of the plasma membrane, thus 
allowing As-ODNs to enter the cells by diffusion. 
Transitory pores are formed in the cell membrane, 
either chemically by streptolysin O [37], or 
mechanically by electroporation [38], shockwave 
or ultrasound waves [39].
Surprisingly, though delivery vehicles are 
essential for the uptake and effi cacy of As-ODNs 
in vitro, most of the As-ODN drugs in clinical tri-
als are being administered as saline solutions 
without delivery vehicles. While it is possible that 
As-ODN uptake in vitro might be different from 
in vivo uptake and endosomal/lysosomal sequestra-
tion might not be a problem in vivo, the widely 
accepted dogma is that the presence of “endoge-
nous biological carriers” facilitates the physiolog-
ical delivery of As-ODNs to the targeted site. 
However, despite numerous reports of As-ODNs 
binding to plasma proteins in vivo, no specifi c 
carrier has yet been identifi ed [40].
Pharmacokinetics of Antisense 
Oligonucleotides
The studies investigating the pharmacokinetic 
properties of As-ODNs have used various routes 
of administration; including subcutaneous (s.c.), 
intradermal (i.d.), intraperitoneal (i.p.) and intra-
venous (i.v.) and topical applications. The 
pharmacokinetic profile of As-ODNs, though 
independent of their length and specifi c sequence, 
is infl uenced by their chemical composition.
PS-ODNs readily bind serum proteins, espe-
cially albumin and α-2 macroglobulin, which 
prevents rapid clearance by glomerular fi ltration, 
thus prolonging the plasma half life of these drugs 
and providing them the opportunity to be distrib-
uted to the peripheral tissues [41]. At clinically 
relevant doses, more than 90% of PS-ODN is 
bound to plasma proteins [42]. The binding affi n-
ity for serum proteins is species dependent and 
follows this order; guinea pig  rat  rabbit  
human [40]. However, the serum protein binding 
is saturable, resulting in excretion of intact oligo-
mers at higher doses [43].
There is rapid clearance of PS-ODNs, following 
i.v. administration, with a plasma half life of less 
than an hour and the concentrations becoming 
undetectable within 5–6 hours. The assays per-
formed with radio labelled ODNs show that the 
plasma clearance is bi-phasic and the terminal 
elimination half life is around 40–60 hours [43].
In the body, the PS-ODNs are widely distributed 
to the tissues, with the peak concentrations in 
highly perfused organs such as liver, kidney and 
spleen [44]. The tissue half life of PS-ODNs is 
much longer, ranging from one to fi ve days, though 
only barely detectable levels of full length ODNs 
281
Advances in antisense oligonucleotide development
Gene Regulation and Systems Biology 2008:2 
are present in tissues after 48 hours [45]. PS-ODNs 
are distributed not only to the tissues but are also 
able to penetrate the cells in the tissues. Even 
though at early time points after PS-ODN injection 
most of it is associated with extracellular matrix 
and connective tissue, by 24 hours almost all of it 
is found within the cells [46].
The metabolism of PS-ODNs, primarily medi-
ated by endo and exo nucleases, results in shorter 
nucleotides, and ultimately nucleosides, that are 
degraded by normal metabolic pathways. The 
elimination of PS-ODNs is mainly through urine 
[47] and to a lesser extent through the faeces.
The pharmacokinetics of second and third gen-
eration As-ODNs has also been investigated. The 
second generation As-ODNs have a rapid plasma 
distribution phase of 4–6 hours, followed by a 
slower distribution phase [48]. The second genera-
tion ODNs are rapidly distributed to the tissues, with 
the highest concentration in liver, kidney and spleen, 
and have a tissue half life of 22 days [49]. The third 
generation As-ODNs, such as MFs, also exhibit a 
favorable pharmacokinetic profi le. They have high 
aqueous solubility and stability [50]. Systemic 
administration of MFs is followed by a rapid distri-
bution phase of 1–4 hours and a plasma half life of 
1–9 hours. The accumulation is rapid in the various 
organs, especially in the liver and kidney. Elimina-
tion is mainly by urine and faeces [51].
Potential Side Effects of Antisense 
Oligonucleotides
A number of studies have extensively studied the 
toxicological profi le of As-ODNs in various spe-
cies including mice, rats, monkeys and humans 
and show that all three generations of As-ODNs 
have an acceptable safety profi le.
Studies of the most commonly used As-ODNs, 
PS-ODNs, show that the modifi cations in back-
bone result in non-specifi c protein interactions. 
This is because, as PS-ODNS are more negatively 
charged as compared to phosphodiester ODNs, 
their polyanionic nature enhances their affi nity for 
proteins, such as heparin-binding proteins, cell 
surface proteins, viral protein CD4, HIV glycopro-
tein 120, epidermal growth factor receptor (EGFR), 
platelet-derived growth factor (PDGF) and certain 
isoforms of protein kinase C (PKC), resulting in 
non-specifi c side effects. For example, PS-ODNs 
can induce autophosphorylation of EGFR and thus, 
prevent the binding of EGF to its receptor [52].
Most commonly reported serious dose limiting 
acute toxicities of As-ODN administration are: 
transient activation of the complement cascade, 
prolongation of partial thromboplastin time (PTT), 
thrombocytopenia and elevation of serum trans-
aminases. Most of these toxicities are the result of 
non-specifi c interactions between As-ODNs and 
plasma proteins. For example, PS-ODNs may 
interact with factor H, a circulating negative regu-
latory factor, leading to activation of the comple-
ment cascade via an alternative pathway, resulting 
in increased complement split products, such as 
C3a and C5a, and subsequent cardiovascular 
events, such as hypotension. The altered clotting 
profi le can be due to PS-ODNs binding to multiple 
coagulation factors, such as VIIIa, IXa, X and II, 
leading to a transient self-limited prolongation of 
activated partial thromboplastin times [53]. More-
over, PS-ODNs with four or more contiguous 
guanosine residues can form quadruple-stranded 
tetraplexes and other higher-order structures, 
where each guanosine residue is hydrogen bonded 
to another guanosine in the quartet. These highly 
negatively charged molecules can be extremely 
biologically active, resulting in non-specifi c side 
effects, such as inhibition of smooth muscle pro-
liferation or induction of bone marrow macrophage 
progenitor cells proliferation [54, 55].
As-ODNs containing CpG motifs result in 
stimulation of the immune response in mammalian 
systems. This is because CG dinucleotide is more 
frequently found in viral and bacterial DNA than 
in the human genome and is usually present in the 
methylated form in the vertebrate system. There-
fore, unmethylated CpG motifs normally act as a 
marker for the immune system to signify infection 
[56]. Various types of immune cells have pattern 
recognition receptors that can recognize unmethyl-
ated CpG dinucleotides, resulting in stimulation of 
immune cells [57]. Unmethylated CpG dinucleo-
tides produce immune responses similar to T-helper 
type 1 (TH1)-cell responses, resulting in the activa-
tion of natural killer (NK) cells, dendritic cells, 
macrophages and B cells [58]. The stimulation of 
the immune system by CpG dinucleotides can 
result in splenomegaly, lymphoid hyperplasia and 
diffused infi ltration of mixed mononuclear cells in 
multiple organs [59].
A lot of attention has been paid to genotoxicity 
of As-ODNs. This is because theoretically, 
there is risk of As-ODNs getting integrated 
into the human genome, resulting in mutagenesis. 
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In addition, there is the risk of ODNs being 
degraded to carcinogenic or mutagenic metabo-
lites [60]. However, studies of As-ODNs in pri-
mates and rodents have shown no evidence of 
teratogenic effects or changes in reproductive 
performance or fertility [61].
It is important to note that As ODNs are gener-
ally safe at therapeutic doses. The As-ODN induced 
toxicities occur at a dose exceeding the therapeutic 
dose normally used in the clinical trials [59]. More-
over, modifi cations in the chemistry of As-ODNs 
have resulted in safer toxicity profi les, with lesser 
stimulation of the immune system and fewer non-
specifi c effects as compared to fi rst generation 
As-ODNs [62].
Antisense Oligonucleotides 
in Therapeutic Intervention
The fi rst drug trial for As-ODNs, conducted in 1992 
for the treatment of leukemia [63], fuelled opti-
mism about the therapeutic potential of As technol-
ogy. However, a mounting amount of evidence 
showed there were non-specifi c effects of As-
ODNs, creating doubts about the clinical suitabil-
ity of As-ODN drugs. After numerous clinical 
trials, Vitravene (ISIS Pharmaceuticals), developed 
for the treatment of cytomegalovirus (CMV) 
induced retinitis in AIDS patients, became the fi rst 
drug to get United States Food and Drug Admin-
istration (FDA) approval. The past decade has seen 
an exponential increase in the use of As-ODNs in 
various in vitro and in vivo models, where As-
ODNs are being explored as potential therapeutics 
against cancer, viral infections, and infl ammatory 
diseases, among a multitude of other diseases. 
More importantly, the effectiveness of more than 
30 therapeutic As-ODNs is currently being tested 
in clinical trials some of which are listed in Table 1. 
The growing optimism about As therapeutics is 
due to the certain advantages this technology has 
over traditional therapeutic interventions, some of 
which are discussed below.
Rational drug design
Rational drug design for any disease requires the 
identification of an appropriate target and the 
development of a drug with a specifi c affi nity to 
that target. In contrast to some drugs, where the 
mechanism of action is not well understood, As 
therapeutics is based on the well defi ned principle 
of Watson Crick hybridization and the ability of 
As-ODNs to bind the target mRNA in a sequence 
specifi c manner resulting in the knockdown of 
target gene. Thus, the use of As-ODNs permits the 
treatment of almost any disease that is linked to a 
dysregulated gene expression.
Easy synthesis
The ease of synthesis of As-ODNs is by virtue of 
the fact that the only information that is required 
for synthesis is the target mRNA sequence. From 
the fi rst use of manually synthesized ODNs in 
1977, As-ODN technology has progressed to a 
stage where automated synthesis of oligonucle-
otides can be commercially done on a mass scale 
in weeks. Various computational algorithms that 
aid in designing potent As-ODNs are commercially 
available. These include oligonucleotides array, 
RNAse H mapping and mRNA walking. The mfold 
and sfold programs available in the public domain 
are also widely used for predicting the structure of 
the target mRNA sequence [53].
The progress in the use of As-ODN technology 
has been further facilitated by the advances in the 
fi eld of nucleic acid chemistry. Now it has become 
easy to synthesize a stable complementary ODN 
sequence, that will hybridize to the sense strand 
with high affi nity and inhibit its function, as long 
as the sequence of the gene and consequently the 
target mRNA is known.
Specifi city
The specifi city of Watson- Crick hybridization 
between As-ODN and mRNA suggests that the 
use of As-ODNs will result in sequence specifi c 
downregulation of protein. The use of As-ODNs 
permits the knockdown of a specifi c target protein, 
from a group of closely related proteins, at the 
mRNA level.
In addition, as the pattern of gene expression 
varies between normal cells and diseased cells, 
such as tumour cells, As-ODNs can be used spe-
cifi cally against mutated or tumour associated 
genes without affecting the expression of proteins 
in normal cells.
Accessibility
As opposed to the conventional treatment, directed 
at a wide range of cellular targets, the more recent 
focus in drug development has shifted mainly to 
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inhibition of individual proteins. However, because 
of their intracellular localization, not all proteins 
are accessible to small molecules (e.g. inhibitors 
of cell signalling proteins such as kinases) or mac-
romolecular antibodies, whose use is mostly lim-
ited to cell surface receptors and secreted proteins, 
due to their ineffi cient delivery into the cells. As-
ODNs, on the other hand, offer the opportunity to 
target those proteins, at the gene expression level 
in vivo, that can not be easily targeted by other 
available pharmacological tools [64].
Ease of translation/direct clinical application
Another advantage of As technology is that the 
oligonucleotides that have been used for inhibition 
of gene expression in the cell culture system and 
have shown therapeutic benefi t in the treatment of 
a disease, can be used directly in animal models of 
the disease and for the disease treatment in humans. 
Thus, the use of As-ODNs is advantageous, as 
opposed to some of the traditional target validation 
approaches, that might be useful in preclinical 
models for target identifi cation but are unsuitable 
Table 1. Antisense oligonucleotides in clinical trials.
As ODN Company mRNA Target Chemistry Delivery Clinical 
phase
Study group
G3139 
(Oblimersen)
Genta Bcl-2 PS Systemic Phase 
I,II,III
CLL, Malignant 
melanoma,
Multiple myeloma,
NSCLC, AML
RESTEN-MP AVI c-myc MF Systemic Phase II Restenosis
ISIS 2503 Isis H-ras PS Systemic Phase II NSCLC, breast, 
colorectal
and pancreatic 
cancer
LErafAON-ETU NeoPharm raf kinase PS Systemic Phase I Advanced cancer
OGX-011 OncoGenex Clusterin Gapmer Systemic Phase II NSCLC, Prostate 
and breast cancer
ISIS 3521 
(Affi nitak)
Isis/Eli Lilly PKCα PS Systemic Phase III NSCLC
GTI 2040 Lorus Ribonucleotide 
reductase
PS Systemic Phase II Renal cancer
LR3001 Genta c-myb PS Systemic Phase I CML
GEM 231 Hybridon PKA Gapmer Systemic Phase I,II Solid cancers
MG98 Methylgene DNA 
methyltransferase
Gapmer Systemic Phase II Head,neck and 
metastatic renal 
cancers
AP 12009 Antisense
Pharma
TGF-β2 PS Intra 
tumoral
Phase II Glioma, malignant 
melanoma,
pancreatic cancer
ISIS 2302 
(Alicaforsen)
Isis ICAM-1 PS Systemic/ 
enema
Phase II Ulcerative colitis
EPI-2010 EpiGenesis Adenosine A1R PS Aerosol Phase II Asthma
ISIS 104838 Isis TNF-α Gapmer Subcuta-
neous
Phase III Rheumatoid arthritis
GEM 92 Hybridon HIV gag Gapmer Oral Phase II HIV
Abbreviations: As-ODN: antisense oligonucleotide; PKCα: protein kinase C α; PKA: protein kinase A; TGF-β2: transforming growth factor 
β-2; ICAM-1: intracellular adhesion molecule-1; Adenosine A1R: adenosine A1 receptor; TNFα: tumour necrosis factor α; HCV: hepatitis C 
virus; HIV: human immunodefi ciency virus; PS: phosphorothioate; MF: morpholino; CLL: chronic lymphocytic leukemia; NSCLC: non-small 
cell lung cancer; AML: acute myelogenous leukemia; CML: chronic myelogenous leukemia.
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for human use. In fact many of the As-ODN drugs 
that are currently in clinical trials were used initially 
for target identifi cation in in vitro systems.
Antisense Oligonucleotides 
in Cancer Therapeutics
Since the fi rst trial to knock down N-Myc protein 
in vivo [65], tremendous progress has been made 
in the fi eld of oncology with encouraging results. 
The main focus is on the knockdown of the genes 
that become upregulated during tumorogenesis 
such as the genes involved in apoptosis, cell growth 
and survival, angiogenesis and metastasis.
Of these, the most promising candidates for 
antisense therapy are those molecules that have 
been shown to be causally related to cancer pro-
gression or therapeutic resistance and are not 
amenable to inhibition by the conventional therapy 
[66]. Some of the main targets of As-ODNs in 
cancer therapeutics are discussed below.
Bcl-2
Bcl-2 is a mitochondrial-membrane protein with 
the ability to block the apoptosis. Over-expression 
of Bcl-2 has long been linked to tumorogenesis 
and chemoresistance, suggesting that targeting this 
gene can enhance chemotherapy-induced apopto-
sis [67]. Pre-clinical, in vitro and in vivo, studies 
have shown that anti-Bcl-2 As-ODNs can induce 
apoptosis in cells derived from solid tumours and 
sensitize tumour cells to the effect of chemotherapy 
[68, 69]. G3139 (Oblimersen, also called Genas-
ense; Genta Inc.) is an 18 base PS-ODN targeting 
the fi rst six codons of the Bcl-2 mRNA open read-
ing frame [70]. Numerous clinical trials have 
employed G3139 to treat a variety of cancers, such 
as Multiple Myeloma, Malignant Melanoma, 
Chronic Lymphocytic Leukaemia (CLL), Non- 
Hodgkin’s Lymphoma (NHL), breast cancer and 
Small Cell Lung Cancer (SCLC). The results 
of several phase I and phase I/II trials of G3139 
have been reported [71, 72], showing that Bcl-2 
As therapy resulted in the specifi c downregulation 
of Bcl-2, without signifi cant toxicity at clinically 
relevant doses, and therefore has potential for the 
treatment of cancers, which have Bcl-2 over-
expression, resistant to conventional therapy. The 
drug is currently in phase II and II/III of clinical 
trials, either alone or in combination with 
chemotherapy, for a variety of cancers. Recently 
published results of a randomized phase III trial in 
patients with metastatic melanoma, comparing the 
treatment with a combination of dacarbazine 
and G3139 to dacarbazine alone, have failed 
to reveal clinically meaningful results [73]. How-
ever, in the group of patients who achieved antitu-
mour response, use of G3139 and dacarbazine 
combination therapy produced a significant 
increase in progression-free survival, as compared 
to patients receiving dacarbazine alone. Results 
from other clinical trials will help to determine the 
effi cacy of this drug.
Protein kinase C α
Protein kinase C α (PKCα) is a member of family 
of the cytoplasmic serine-threonine protein kinases 
involved in a myriad of signal transduction path-
ways controlling cell proliferation. There are 13 
isoforms of PKC and currently available inhibitors 
and modulators of PKC activity are limited by their 
inability to differentiate between the various iso-
zymes. Therefore, several As-ODNs, which spe-
cifi cally target individual members of the PKC 
family, are being used to study the various isoforms 
of this enzyme. Over-expression of PKCα has been 
implicated in oncogenesis and tumour progression 
[74]. Several in vitro and in vivo studies have 
shown that As-ODNs targeted against PKCα can 
inhibit tumour growth [75–77]. The effi cacy and 
safety profi les of these results encouraged the 
human trials of PKCα-specifi c 20 mer PS-ODN, 
ISIS 3521 (also referred to as Affi nitak, Aprino-
carsen and LY90003; Isis Pharmaceuticals), 
complementary to the 3’-untranslated region of 
PKCα mRNA. The phase I trials of ISIS 3521 were 
carried out successfully in patients with treatment-
resistant solid tumours [78–80]. The therapy was 
well tolerated and showed benefi t in some cases. 
Dose-limiting toxicities, moderate fatigue and 
thrombocytopenia, were encountered at doses of 
3 mg/kg per day. Therefore, the dose for Phase II 
trial was set at 2 mg/kg/day, which corresponded 
with doses showing antitumour activity in xeno-
graft models. Phase I/II studies, evaluating the 
combination therapy of ISIS 3521 and chemo-
therapeutic agents, were initiated in patients with 
stage III B or IV NSCLC [81]. The drug combina-
tions were well tolerated with acceptable toxicity 
profi les. Based on phase II, results two phase III 
randomized trials were initiated in patients with 
NSCLC. The results failed to show any benefi t in 
terms of median survival rate in the group receiving 
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ISIS 3521 (ISIS Pharmaceuticals). Disappointing 
results have also been shown in a phase II trial of 
ISIS 3521, in patients with metastatic colorectal 
cancer, with very little uptake of the drug in tumour 
cells and no evidence of signifi cant knockdown of 
PKCα expression [82]. More studies need to be 
done to evaluate the effi cacy of this drug.
H-ras
The proteins encoded by members of the ras family 
serve as critical components of the cell-signaling 
pathway and are involved in the control of cellular 
proliferation, differentiation, and cell death. Muta-
tions in the genes encoding the Ras family of pro-
teins result in abnormal cell growth and malignant 
transformation. Activating mutations in the ras 
family of genes are found in over 30% of human 
tumours [83], making ras a promising therapeutic 
target. A 20 mer PS-ODN, ISIS 2503 (ISIS Phar-
maceuticals), targeted to the translation initiation 
region of H-ras mRNA selectively reduced the 
expression of H-ras protein in vitro [84]. In various 
phase I clinical trials ISIS 2503 did not show any 
dose limiting toxicity. However, no consistent 
decrease in H-ras mRNA, levels, in peripheral 
blood lymphocytes, was observed [85].
A combination of ISIS 2503 and gemcitabine, 
in metastatic or locally advanced pancreatic 
adenocarcinoma, showed a promising response 
rate, but no clear deductions could be made about 
the overall benefi t for this combination therapy, 
warranting further evaluation of the effi cacy of 
ISIS 2503 [86].
c-raf
Raf kinases, members of the family of serine/
threonine protein kinases, are downstream media-
tors of mitotic signalling pathways. Most notably, 
raf-1 plays a central role in the mitogen activated 
protein kinase (MAPK) pathway and is activated 
by ras protein [87]. Raf has also been reported to 
bind to Bcl-2 and to be indirectly involved in the 
regulation of apoptosis [88]. Mutations of the raf 
proteins, resulting in their constitutive activation, 
have been identifi ed in many tumours [89]. There-
fore, targeting raf seems to be an attractive option 
for the treatment of diseases associated with abnor-
mal cell proliferation. In a screening study com-
prising 34 different As-ODN sequences, a 20 mer 
PS-ODN (ISIS 5132; ISIS Pharmaceuticals), 
directed to the 3’ untranslated region of the c-raf 
mRNA, resulted in a most potent inhibition of the 
growth of human tumour cell lines in vitro and 
in vivo [90]. ISIS 5132 was shown not only to 
decrease c-raf expression but also to increase 
tumour sensitivity [91]. In a phase I trial, changes 
in the expression of c-raf1 mRNA were assessed 
in peripheral blood mononuclear cells, collected 
from patients with advanced cancers treated with 
ISIS 5132. Signifi cant reductions from baseline 
were detected in the expression of c-raf1 [92]. 
Results of other phase I clinical trials of ISIS 5132, 
conducted in patients with a variety of advanced 
solid tumours, showed that the drug is generally 
well tolerated with only mild side effects, which 
were generally the same as those attributed to PS-
ODN treatment. Even though no evidence of sig-
nifi cant tumour regression was observed in these 
trials, several of the patients experienced long 
periods of disease stabilization [93–95]. The anti-
tumour activity of ISIS 5132 has been evaluated 
in phase II studies in patients with colorectal can-
cer, ovarian cancer, hormone refractory prostate 
cancer, small cell and non small cell lung cancers 
[96–99]. Again no clinically signifi cant tumour 
regressions were observed, but protracted periods 
of stable disease were observed in some patients.
Another raf-1 As-ODN, LErafAON (Neo-
Pharm), a 15-mer As-ODN directed to the transla-
tion initiation site of c-raf-1 mRNA, has also 
entered clinical trials. The PS modifi cation of this 
As-ODN is limited only to the terminal base at the 
3’ and 5’end [100]. LErafAON has been encapsu-
lated in a cationic liposome in order to protect the 
ODNs from degradation and to improve their serum 
half life. Preclinical studies of this drug have shown 
inhibition of tumour growth, more than 50% inhibi-
tion of raf-1 expression in tumour xenografts and 
increased sensitization of tumour cells to radiation 
and to chemotherapeutic agents [101, 102]. Phase I 
study of LErafAON has shown that the i.v. delivery 
of drug is well tolerated along with palliative 
radiotherapy [103]. A phase I dose-escalation trial, 
using a weekly bolus regimen of LErafAON in 
patients with advanced solid tumours, has shown 
dose-independent hypersensitivity reactions and 
dose-dependent thrombocytopenia, limiting toler-
ance of the drug [104]. Another phase I study of 
combined modality treatment using LErafAON and 
radiation therapy, in patients with advanced 
tumours, has shown that the combination is well 
tolerated. However, pre-medication with steroids 
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and antihistamines was needed to control the 
infusion related reactions. Therefore, modifi cations 
are being made in liposomal formulation to improve 
the tolerability of LErafAON [105].
Antisense Oligonucleotides
in Viral Therapeutics
A lot of attention is currently being paid to the 
treatment of viral cytopathic effects by As-ODNs. 
Many valuable contributions have been made to 
the As-ODN antiviral strategies by studies involv-
ing various viruses, such as Herpes Simplex virus 
(HSV), Human Immunodefi ciency Virus (HIV), 
Cytomegalovirus (CMV), Hepatitis B virus (HBV), 
Hepatitis C virus (HCV), Epstein—Barr Virus 
(EBV) and many more. Some of the antiviral As-
ODNs are discussed below.
Cytomegalovirus (CMV)
Cytomegalovirus (CMV) belongs to the Herpes-
viridae family of viruses, which are DNA viruses 
that exhibit the biological properties of latency and 
reactivation. In the developed countries, up to 80% 
of individuals develop sub-clinical CMV infections. 
In most of the cases, the primary CMV infections 
go unrecognized, however, in immunocompromised 
patients, CMV infections are one of the major causes 
of morbidity and mortality [106]. CMV retinitis is 
one of the most common opportunistic infections in 
patients with acquired immunodefi ciency syndrome 
(AIDS). AIDS patients infected with CMV retinitis 
can develop either intolerance or resistance to com-
monly used anti-CMV treatment regimens, neces-
sitating the development of alternative treatment 
options [107]. One such option is the use of As-
ODNs for the inhibition of CMV replication. Much 
of the research on inhibition of CMV replication by 
As-ODNs has mainly focused on inhibition of CMV 
immediate-early (IE) gene products. In one of the 
early studies, PS-ODNs complementary to the 
mRNA of the CMV DNA polymerase gene or to 
RNA transcripts of the major immediate-early 
regions 1 and 2 (IE1 and IE2), showed antiviral 
activity. ISIS 2922 (Fomivirsen also called Vit-
ravene ; ISIS Pharmaceuticals), a PS-ODN with a 
21 nucleotide sequence complementary to RNA of 
IE2, showed at least 30 fold more potent antiviral 
activity as compared to nucleoside analog gangci-
clovir. The results showed that ISIS 2922 inhibits 
viral production in a specifi c and dose dependent 
manner [108]. Subsequent reports showed that 
antiviral activity of ISIS 2922 is because of anti-
sense, non-antisense sequence dependent and 
sequence independent mechanisms. Base comple-
mentarity to target RNA was important for optimal 
activity of ISIS 2922 in antiviral assays, but base 
changes affecting parameters other than hybridiza-
tion affi nity also infl uenced antiviral activity. More-
over, the drug also caused sequence-independent 
inhibition of virus adsorption to host cells at high 
concentrations [109]. Following encouraging data 
about the antiviral activities of ISIS 2922, clinical 
trials of the drug were carried out for the treatment 
of CMV retinitis in AIDS patients. The results of 
phase I, II and III trials showed intravitreal injections 
of ISIS 2922 to be safe and effective. The drug 
halted the progression of both acute and chronic 
CMV retinitis in AIDS patients. Moreover, the local 
treatment with the drug reduced the incidence of 
systemic side effects. Most commonly reported side 
effects were increase in intraocular pressure and 
mild to moderate intraocular infl ammation, both of 
which were transient or treatable with topical steroid 
treatment [110, 111]. Following the successful 
clinical trials, in 1998, ISIS 2922 was approved by 
FDA, for the treatment of CMV-induced retinitis in 
patients with AIDS and became the fi rst As-ODN 
drug to be marketed commercially [112].
Human immunodefi ciency virus (HIV)
HIV is a single stranded RNA virus that uses reverse 
transcriptase (RT) to create a DNA copy of its RNA 
genome. The viral DNA then gets integrated into 
the DNA of the host, and is subsequently tran-
scribed and translated by the host cell. HIV infection 
is spreading worldwide at an alarming rate, repre-
senting the diffi culties in controlling viral replica-
tion. Many regions of the HIV genome have been 
targeted with As-ODNs, including the rev, tat, gag, 
pol, and env genes, 5’untranslated region and psi 
sequences. Various ODNs have been shown 
to be effective in acute and chronic infections 
[113–115]. GEM 91 (Hybridon), a 25-mer PS-ODN 
that binds to the translation initiation site of 
the HIV gag mRNA, was shown to effectively 
reduce HIV replication in vitro [116]. Although 
the initial reports of GEM 91 clinical trials showed 
it to be well tolerated [117], its use was later 
discontinued because of dose-limiting thrombocy-
topenia and elevated serum transaminase levels. 
GEM 92 is an orally administered second generation 
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As-ODN synthesized on a truncated GEM 91 
sequence [118]. GEM 92 is currently in phase I 
clinical trials, with preclinical studies showing an 
improved stability and safety profi le [118].
Hepatitis C virus
Chronic infection by HCV is the most common 
cause of hepatocellular carcinoma, and is the pri-
mary reason for liver transplantations among adults 
in the western world. However, currently available 
anti-HCV compounds are not broadly effective, 
especially against the chronic HCV infection. There-
fore, continuous efforts are being made to develop 
newer and better therapeutic strategies [119]. 
Recently, much attention is being paid to the use of 
As-ODNs for the treatment of HCV infection. Sev-
eral As-ODNs that have been designed to bind to 
the stem-loop structures in the HCV Internal Ribo-
some Entry Sites (IRES) have been shown to be 
effective in inhibiting HCV replication in cell-
culture assays [120, 121]. The expression of HCV 
luciferase reporter gene was shown to be inhibited 
significantly by PS-ODN in the livers of mice 
infected with recombinant vaccinia virus expressing 
the reporter construct [122]. ISIS 14803 (ISIS Phar-
maceuticals), a 20-nucleotide, 5’-methylcytidine 
PS-ODN, is being evaluated in phase I and II of 
clinical trials involving patients with chronic HCV 
infections [123]. The compound administered, 
intravenously or subcutaneously, 3 times weekly 
did demonstrate a signifi cant decrease in HCV RNA 
levels for a small sub-group of participants, how-
ever: many of the patients experienced frequent 
elevations in hepatic transaminase levels, raising 
doubts about the suitability of this drug [124].
Antisense Oligonucleotides 
in Allergic, Infl ammatory 
and Autoimmune Diseases
As-ODNs have been explored for their therapeutic 
benefi ts in various allergic and infl ammatory dis-
eases e.g. in bronchial asthma, Crohn’s disease 
(CD), Ulcerative colitis (UC), psoriasis. Some of 
the important targets of As-ODN therapy for these 
disease models are discussed below.
Intercellular adhesion molecule-1 
(ICAM-1)
ICAM-1 is a transmembrane glycoprotein that is 
constitutively expressed at low levels by vascular 
and colonic endothelium and a subset of leucocytes 
[125]. Surface expression of ICAM-1 is increased 
in response to various infl ammatory stimuli, result-
ing in the adhesion and recruitment of monocytes, 
macrophages, neutrophils, T lymphocytes and 
dendritic cells (DCs) to the site of infl ammation 
[126]. Thus, theoretically, it seems likely that 
inhibiting the expression of ICAM-1 by As-ODNs 
would hinder the migration of immune cells, result-
ing in a potent immunosuppressive effect. Results 
from pre-clinical studies showed that using As-
ODNs targeted to ICAM-1 results in a decreased 
receptor expression and reduction in infl ammation 
[127]. ISIS 2302 (Alicaforsen; ISIS Pharmaceuti-
cals) is a 20 base PS-ODN that binds to the 
3’-untranslated region of the mRNA and prevents 
further translation, resulting in knockdown of 
ICAM-1 expression [128]. Several placebo-
controlled randomized trials with an ISIS 2302 
have been performed in active steroid-treated 
Crohn’s Disease (CD). The pilot phase I study 
involving 20 participants showed significant 
therapeutic benefi t in chronically active CD [129]. 
The initial enthusiasm was, however, dampened 
by the two follow-up large multicenter phase II 
trials, using subcutaneous and i.v. formulations of 
the drug, which showed no signifi cant difference 
between the placebo and treatment arms [130, 131]. 
On the other hand, ISIS 2302 enema formulation 
has shown signifi cant acute and long term benefi ts 
with favourable safety profi le in Phase I and II 
trials, in patients with mild to moderate descending 
ulcerative colitis (UC) and chronic pouchitis [132, 
133]. Following these encouraging reports, further 
trials using ISIS 2302 enema were carried out in 
patients with UC. The results of these trials suggest 
a more long term reduction in disease activity in 
patients receiving ISIS 2302 enema, compared to 
patients receiving placebo or mesalazine, used 
normally for the treatment of mild-moderate left 
sided UC [134, 135]. Another recently published 
phase I/II study has shown that ISIS 2302 enema 
is useful for the treatment of local infl ammation in 
patients with active UC and has low systemic 
bioavailability and exposure [136].
ISIS 2302 has also been evaluated in combina-
tion with a cyclosporine-prednisone regimen in 
phase I and II trials for the prophylaxis of acute 
allograft rejection [137]. Even though ISIS 2302 
was well tolerated, no signifi cant differences were 
noted, in terms of acute graft rejection or improved 
graft survival, among the patients receiving 
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cyclosporine-prednisone alone or in combination 
with ISIS 2302. Further evaluation of ISIS 2302 
needs to be done to determine its usefulness for the 
treatment of various infl ammatory conditions.
Tumour Necrosis Factor-α (TNFα)
TNFα is a potent pleiotropic cytokine that is pro-
duced by most cells of the body but especially by 
cells of monocyte lineage. TNFα plays an important 
role in the initiation of a vigorous cell and antibody 
mediated immune response and in expansion of the 
required lymphocyte populations [138]. Therefore, 
it is not surprising that targeting TNFα has been 
the focus of for the treatment of rheumatoid arthri-
tis and other infl ammatory conditions. ISIS 104838 
(ISIS Pharmaceuticals), a 20 nucleotide gapmer 
targeting the mRNA of human TNFα, is the fi rst 
As-ODN belonging to the second generation to be 
tried in clinical trials [139]. The preclinical studies 
with ISIS 104838 showed it to be effective for the 
treatment of collagen induced arthritis with activity 
comparable to that by anti- TNFα antibody [140], 
and that it successfully knocks down TNFα expres-
sion by 85% in stimulated keratinocytes [48]. In 
phase I of clinical trials, ISIS 104838 was admin-
istered either by i.v. or s.c routes [48]. The drug was 
well tolerated, the principle side effects being red-
ness at the site of injection and prolongation of PTT 
that was transient and was not associated with 
bleeding. As expected of a second generation 
As-ODN, ISIS 104838 had a longer plasma half 
life, with a terminal plasma half life of two weeks. 
Moreover, in the blood obtained from study subjects 
and then stimulated with LPS, ex vivo production 
of TNFα was signifi cantly decreased in a dose 
dependent manner. ISIS 104838 is currently in 
phase II of clinical trials for the treatment of rheu-
matoid arthritis (RA) and CD.
Adenosine Receptor-1 (AR-1)
Adenosine is a ubiquitous purine nucleoside, nor-
mally present at low concentrations in the extracel-
lular space, but its levels are greatly increased 
under metabolically stressful conditions. An 
increasing amount of evidence suggests that ade-
nosine is a pro-infl ammatory mediator that induces 
bronchoconstriction in animal models and in 
patients with infl ammatory airway diseases, such 
as asthma and chronic obstructive pulmonary 
diseases (COPD) [141]. Adenosine receptor, AR-1 
has been shown to be up-regulated in bronchial 
smooth-muscles of asthmatic patients, in animal 
models of the disease [142, 143] and in bronchial 
smooth-muscle tissue exposed to human asthmatic 
serum [144]. Respirable As-ODNs (RASONs), as 
compared to systemically administered As-ODNs, 
offer the potential to selectively downregulate the 
AR-1 expression in the lung at much smaller doses 
and also minimize the risk of systemic side effects 
and toxicity. Moreover, lungs are lined with sur-
factant that contains cationic lipids, resulting in 
enhanced uptake of As-ODNs [145]. EPI 2010 is 
a RASON designed to target the initiation codon 
of the human A1 receptor mRNA [146]. The pre 
clinical studies with this drug have shown it to be 
specifi c, effective and safe [147, 148]. EPI 2010 
was able to block airway hyper-responsiveness 
(AHR) to inhaled adenosine for several days. 
Therefore, once weekly administration was 
selected for the treatment of asthma during phase I 
clinical trials. Results of Phase I/IIa clinical trials 
have shown EPI-2010 to be safe and well-tolerated, 
with modest indications of effi cacy in patients with 
mild asthma [149]. Further clinical trials are ongo-
ing to determine its clinical effi cacy.
Antisense Oligonucleotides in 
Target Indentifi cation/Validation
The past two decades have seen a dramatic shift 
in the way the pharmaceutical companies approach 
the development of new drugs. Traditionally, the 
compounds were investigated for their biological 
effects fi rst, such as the effect of anticancer agents 
on cell proliferation, and were sometimes marketed 
even before their exact mode of action was known. 
A classic example of this is the commercial use of 
aspirin long before its biological target was identi-
fi ed. This approach, though successful in some 
cases, also resulted in many failures due to various 
factors such as, insuffi cient specifi city of the com-
pound, unsuitability of the target etc [150]. Con-
sequently, the pharmaceutical companies suffered 
enormous losses. To circumvent these problems, 
many companies have now adopted a “target 
directed” approach. The main goal is to understand 
the cellular mechanisms responsible for various 
diseases and to investigate if downregulating a 
certain target protein would produce the desired 
biological effects. The information thus obtained 
is then used to develop new drugs [150].
It had always been a challenge to elucidate the 
function of only one particular isoform of a 
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protein, while leaving the other isoforms intact. 
Moreover, the use of various small molecule 
inhibitors, such as kinase inhibitors, for target 
identifi cation/validation was confounded by the 
problems of specifi city. For example, SB203580 
and PD 98059, in addition to inhibiting p38 and 
p44/42 MAPKs, have been shown to inhibit the 
activity of cyclooxygenases and thromboxane 
synthase [151]. With the availability of As-ODNs 
it has now become possible to dissect complex 
intracellular signalling cascades with various 
overlapping pathways and to discern the function 
of homologous gene products selectively and 
effi ciently. In addition, the As-ODN knockdown 
of cellular proteins makes it possible to investigate 
their specifi c roles in disease development and 
progression, and to determine if suppressing the 
activity of that particular protein will signifi cantly 
infl uence disease pathophysiology.
After a suitable target has been identifi ed in 
vitro, its validity needs to be confi rmed by in vivo 
evaluation. Knockout gene models have tradition-
ally been used as the gold standard for determining 
the gene functions in vivo. However, their use is 
limited by the length of time required to create and 
characterize the mutant strain. Moreover, mutation 
of certain genes is embryonically lethal making it 
impossible to study them in a knockout animal 
model. The use of As-ODNs permits the study of 
the effect of knockdown of the target gene on the 
whole animal in a rapid manner and at different 
stages of development, ranging from the embryonic 
stage to the adult animal [152].
One example of the use of As-ODNs in target 
identifi cation/validation is the identifi cation of 
Sphingosine Kinase-1 (SPHK-1) as a key player 
in the pro-infl ammatory responses triggered by 
TNFα in human monocytes [153] and by C5a in 
human monocyte-derived macrophages [154]. 
Following numerous reports of the role of sphin-
golipid metabolite, S1P, in a variety of cellular 
processes, such as cell differentiation and prolif-
eration, we investigated if decreasing the produc-
tion of S1P, by knocking down SPHK expression, 
would affect the immune cells response to infl am-
matory mediators. We did this by using As-ODNs 
directed to the two known SPHK isoforms, SPHK-1 
and SPHK-2. Our results showed an important role 
for SPHK-1, but not for SPHK-2, in the cellular 
processes triggered by C5a and TNFα. Combined 
with other data, our results suggest that targeting 
SPHK-1 can be a useful therapeutic strategy 
for the treatment of various allergic and infl amma-
tory diseases.
Limitations of Antisense
Oligonucleotides
Despite the apparent simplicity of the principle, 
execution of As therapeutics has been very chal-
lenging. The main limitation of As therapy is the 
single target approach. This is because many dis-
eases are caused by multiple, unrelated genetic 
alterations. Therefore, knocking down the expres-
sion of a single target gene may not be suffi cient 
to infl uence the disease pathogenesis. In phase II 
and phase III of clinical trials many As-ODN drugs 
failed to produce signifi cant therapeutic benefi t 
when used alone for the treatment of cancer. A 
possible explanation is that the proteins regulating 
the cell cycle progression and cell proliferation are 
numerous and redundant. Therefore, even if a 
single target is signifi cantly knocked down, other 
proteins of the same family may be activated and 
compensate for the reduced activity of the knocked 
down protein. One such example is the recently 
published results of a phase III trial of the drug, 
Affi nitak, directed against PKCα (ISIS Pharma-
ceuticals). When used for the treatment of non-
small cell lung cancer (NSCLC), the administration 
of the drug, in combination with chemotherapeutic 
agents, did not result in overall prolongation of 
life, as compared to chemotherapy alone. The most 
likely reason for these rather disappointing results 
is that, as there are 13 isoforms of PKC in mam-
malian cells, knockdown of only one isoform may 
not be suffi cient and may result in another isoform 
taking over its function.
Another problem with antisense knockdown is 
that even though a major reduction in target 
mRNAs can be achieved, a complete 100% inhibi-
tion of proteins is not possible: this is because the 
transcription of endogenous copies of proteins 
cannot be inhibited by As-ODNs. This, though 
useful for the function of normal proteins, can pose 
problems in case of mutated proteins.
Finally, despite extensive research to improve 
their delivery and uptake, the in vivo delivery of 
ODNs still remains one of the major challenges in 
the fi eld of As therapeutics. The need for a sustained 
and effective plasma concentration demands admin-
istration of As-ODNs by repeated or continuous i.v. 
infusions. This not only increases the risk of central 
venous thrombosis and the chances of line infections, 
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but also affects the quality of life of the patients [5]. 
Delivery systems that will facilitate the delivery and 
enhance the sustained release of the As-ODNs are 
needed if As-ODNs are to be incorporated in the 
routine treatment of patients in clinics.
Alternatives to Antisense 
Oligonucleotides
In recent years there has been a tremendous 
increase in interest in RNA interference (RNAi), 
especially small inhibitory RNA (siRNA) and 
microRNAs (miRNAs) as well as ribozymes.
Ribozymes are RNA molecules that act as 
enzymes and have the ability of breaking and/or 
forming covalent bonds with extraordinary speci-
fi city, thereby accelerating the spontaneous rates 
of targeted reactions. Many ribozymes catalyze 
either their own cleavage or the cleavage of other 
RNAs, but they have also been found to catalyze 
the aminotransferase activity of the ribosome 
[155]. Ribozymes occur naturally, but can also be 
engineered artifi cially for expression and targeting 
of specifi c sequences. At least six types of ribo-
zymes have been successfully modifi ed for thera-
peutic and functional genomic applications. Of 
these, the two most commonly used modifi cations 
are “hammerhead ribozymes”, which are around 
30 nucleotides long and cleave the substrate RNA 
at sequence NUH (N-any nucleotide, H-not gua-
nosine) and “hairpin ribozymes” that cleave the 
target RNA immediately upstream of the sequence 
GUC. The hairpin ribozymes can also catalyze the 
ligation reactions [156]. Ribozymes are typically 
expressed from a plasmid vector transfected into 
the target cell, but they can also be produced in 
vitro and administered exogenously. Hammerhead 
and hairpin ribozymes have been successfully used 
to downregulate specifi c cellular and viral targets 
in vitro [157, 158] and in vivo [159]. The success 
of preliminary studies encouraged the clinical tri-
als of ribozymes, especially for the treatment of 
infectious diseases and cancer [160, 161].
RNAi is another method that is being increas-
ingly used for stable inhibition of gene expression. 
RNAi refers to a group of gene silencing mecha-
nisms in which the terminal effector is a 21–23 bp 
RNA molecule. One commonly employed RNAi 
mechanism includes introduction of a long 
‘triggering’ dsRNA with 2-nucleotide overhangs at 
the 3’ terminal end, that is subsequently processed 
into 21–23 bp small interfering RNAs (siRNA), by 
an RNaseIII-like enzyme called Dicer. This enzyme 
also includes a helicase domain, suggesting that 
unwinding of the triggering dsRNA might be 
required for the subsequent target recognition event, 
presumably guided by traditional Watson—Crick 
base-pairing in the enzyme—substrate [ES] com-
plex. This 21–23 bp siRNA species is then incor-
porated into an, as yet, crudely defi ned multi-subunit 
RNA-induced silencing complex (RISC), which 
targets the unique cellular RNA transcript for enzy-
matic degradation. RNA hydrolysis occurs within 
the region of homology directed by the original 
siRNA, thereby selectively inhibiting target gene 
expression. RNA-dependent RNA polymerase 
(RdRp), present in plants but not in vertebrates, 
amplifi es the production of dsRNAs using the anti-
sense strand of siRNA as a template [161]. siRNAs 
have emerged as potent tools to specifi cally knock-
down the target gene expression in a sequence-
specifi c manner [162]. Intense research efforts are 
being made to develop siRNAs for therapeutic 
purposes. Various in vitro and in vivo studies have 
demonstrated the effi cacy of this technology [163, 
164] and some of the siRNA drugs are currently 
being tested in clinical trials [165].
RNAi is related to another gene-silencing mech-
anism that involves a group of small RNA mole-
cules, known as microRNAs (miRNAs). miRNAs 
are 21–24 nucleotide (nt) non-coding single strands 
of RNA that are endogenously expressed and are 
involved in the regulation of mRNA expression. 
Short hairpin precursors called pre-miRNAs are 
processed by Dicer into 21- to 23-nucleotide long, 
miRNA molecules, which are then incorporated into 
RISC. miRNAs then either cause the translational 
repression or degradation of target mRNA depend-
ing upon the extent of complementarity between the 
miRNA and target mRNA. If the target mRNA is 
perfectly complementary to miRNA, miRNA mol-
ecules act in a way similar to siRNAs and induce 
the cleavage of the target mRNA. miRNAs that 
contain partially complementary sequences to the 
3’ untranslated region of mRNAs inhibit their trans-
lation [166, 167]. Since the discovery of fi rst miRNA 
molecules, lin-4 and let-7 in C. elegans, [168, 169] 
many miRNAs have been identifi ed in most of the 
organisms such as viruses, plants and verte-
brates [170]. However, the precise mechanism of 
action and function of most of the miRNAs still 
needs to be further elucidated.
The availability of these alternative approaches 
for sequence-specifi c knockdown of RNA holds 
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great promise in both research and therapeutics, but 
the determining factor in choosing one over the other 
will depend on the cost of production and the ease of 
delivery to the target cells. Moreover, the experiences 
with As-ODN therapeutics will give them an advan-
tage against the relative newness of the alternative 
strategies [171], that are still at the earlier stages of 
their development, have little information available 
about their pharmacokinetics and toxicology and need 
more evidence of their therapeutic potential in vivo.
Conclusion and Future Directions
The past two decades have seen an increasing use of 
As-ODNs for the purpose of target identifi cation/
validation and the use of the information, thus 
obtained, for the development of effective therapeu-
tic interventions. Tremendous progress has been 
made in the understanding and applications of As-
ODNs. Most of the structural motifs in PS-ODNs, 
that interfere with their antisense effects and are 
responsible for toxicities, have been delineated. Many 
desirable properties such as effi cient uptake by the 
cells, stability against nucleases, and a strong affi nity 
for target mRNA have been identifi ed. Effective 
chemical modifi cations are likely to avoid the non-
antisense effects and further enhance the safety and 
effi cacy of As-ODNs and thus expand their potential 
clinical applications. However, more work needs to 
be done to further optimize the stability and bioavail-
ability of As-ODNs. Moreover, proof of principle for 
the biological activity of As-ODNs is needed in the 
clinical samples, in order to confi rm the successful 
blockade of target protein expression [5]. The rather 
disappointing results of some of the recent clinical 
trials indicate a need to clearly establish the relevance 
of the target to the patient population being studied, 
an early determination of optimal biological dose and 
the rational use of combination strategies for the 
treatment of the disease [66]. Finally, the clinical end 
points need to be clearly defi ned in order to evaluate 
the effi cacy of As-ODNs [172].
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